Targeting tumour vasculature by inhibiting activin receptor-like kinase (ALK)1 function

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Angiogenesis is crucial for cancer growth and a therapeutic target.
• Vascular endothelial growth factor (VEGF) pathway inhibitors show limited efficacy and resistance.
• New anti-angiogenic targets are needed to improve cancer treatment outcomes.

Purpose of the Study:

• To review the role of Activin receptor-like kinase 1 (ALK1) in angiogenesis.
• To summarize the preclinical and clinical development of ALK1 inhibitors.
• To discuss future strategies for ALK1-targeted anti-angiogenic therapy.

Main Methods:

• Review of existing literature on ALK1 function in endothelial cells.
• Summary of preclinical data for ALK1 inhibitors (Dalantercept, PF-03446962).
• Analysis of current clinical trial status for ALK1-targeted agents.

Main Results:

• ALK1, a TGF-β type I receptor, is vital for angiogenesis, binding BMP9 and BMP10.
• Two ALK1 inhibitors, Dalantercept and PF-03446962, are in clinical development.
• ALK1 inhibition represents a promising strategy to overcome resistance in anti-angiogenic therapy.

Conclusions:

• ALK1 plays a critical role in regulating blood vessel formation.
• Targeting ALK1 offers a potential strategy to enhance anti-angiogenic therapy efficacy.
• Further research into combination regimens involving ALK1 inhibitors is warranted.